Dr. Gilmore O’Neill holds a substantial stake in Editas Medicine, with performance-based stock units (PSUs) that are key to his wealth. As of 2023, he had about 216,637 PSUs tied to specific R&D milestones, highlighting his commitment and belief in...

Dr. Gilmore O’Neill holds a substantial stake in Editas Medicine, with performance-based stock units (PSUs) that are key to his wealth. As of 2023, he had about 216,637 PSUs tied to specific R&D milestones, highlighting his commitment and belief in the company's prospects. His stock awards align with corporate performance, ensuring that he benefits from the company's success. The current value of his holdings can be seen as both a bet on his leadership and a reflection of his expertise. In 2023 alone, O’Neill's wealth from stock options and awards around Editas reached approximately 2.2 million, evidencing a solid performance and the company's trajectory. It’s noteworthy that his wealth is directly tied to the achievement of ambitious goals, making him a significant player in the biotech space.